Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010
Statements of Operations [Abstract]
Product sales, net	$ 8,378,094	$ 9,749,968
Cost of products sold	3,016,642	3,531,452
Gross profit	5,361,452	6,218,516
Selling, general and administrative expenses	6,445,001	6,648,859
Research and development expenses	140,053	270,494
Total	6,585,054	6,919,353
Loss from operations	(1,223,602)	(700,837)
Other income (expense)
Other income		183,673
Interest income	35	587
Interest expense	(131,838)	(95,135)
Amortized debt issuance	(5,296)	(2,796)
Loss on Earnings from Medical Joint Venture	(121,399)
Total other (expense) income	(258,498)	86,329
Net loss	(1,482,100)	(614,508)
Net loss applicable to common stockholders	$ (1,482,100)	$ (614,508)
Loss per share applicable to common stockholders -- basic and diluted	$ (0.10)	$ (0.04)
Weighted average shares outstanding and to be issued -- basic and diluted	15,174,893	14,824,802